Dagmar Rosa-Bjorkeson
Chief Operating Officer bij MESOBLAST LIMITED
Vermogen: 110 805 $ op 31-03-2024
Profiel
Dagmar Rosa-Bjorkeson is an Independent Director at Xencor, Inc. and a Director at New Jersey City University Foundation and Deirdres House.
They are also the Chief Operating Officer at Mesoblast Ltd.
Ms. Rosa-Bjorkeson previously served as an Independent Director at Intercept Pharmaceuticals, Inc. from 2021 to 2023.
They were the President-Biosimilars & EVP at Baxalta, Inc. from 2014 to 2016 and Vice President & Head-Multiple Sclerosis Business at Novartis Pharmaceuticals Corp.
from 1997 to 2014.
Ms. Rosa-Bjorkeson also held positions at Hoechst Pharmaceuticals Ltd.
as a Sales Representative, Mallinckrodt Medical, Inc. (US) as an Executive VP, Chief Strategy & Development Officer from 2017 to 2020, and Mallinckrodt Plc as the Chief Strategy & Corporate Development Officer from 2018 to 2020.
They have an undergraduate degree, a graduate degree, and an MBA from The University of Texas at Austin.
Ms. Rosa-Bjorkeson's current job(s) include Independent Director at Xencor, Inc., Director at New Jersey City University Foundation, Director at Deirdres House, and Chief Operating Officer at Mesoblast Ltd.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
XENCOR, INC.
0.01% | 20-06-2023 | 5 007 ( 0.01% ) | 110 805 $ | 31-03-2024 |
Actieve functies van Dagmar Rosa-Bjorkeson
| Bedrijven | Functie | Begin |
|---|---|---|
| XENCOR, INC. | Director/Board Member | 18-12-2019 |
| MESOBLAST LIMITED | Chief Operating Officer | 24-07-2020 |
| Deirdres House | Director/Board Member | - |
New Jersey City University Foundation
 New Jersey City University Foundation Other Consumer ServicesConsumer Services The New Jersey City University Foundation operates colleges and educational universities. The private company is based in New Jersey. | Director/Board Member | - |
Eerdere bekende functies van Dagmar Rosa-Bjorkeson
| Bedrijven | Functie | Einde |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Director/Board Member | 08-11-2023 |
| MALLINCKRODT PLC | Corporate Officer/Principal | 01-01-2020 |
Mallinckrodt Medical, Inc. (US)
 Mallinckrodt Medical, Inc. (US) Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Medical, Inc. is a pharmaceutical company based in St. Louis. The American company manufactures pharmaceutical products. | Corporate Officer/Principal | 01-01-2020 |
| BAXALTA INC | Corporate Officer/Principal | 01-01-2016 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01-01-2014 |
Opleiding van Dagmar Rosa-Bjorkeson
| The University of Texas at Austin | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| XENCOR, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| MALLINCKRODT PLC | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
| Hoechst Pharmaceuticals Ltd. | |
Novartis Sverige AB
 Novartis Sverige AB Pharmaceuticals: MajorHealth Technology Novartis Sverige AB trades pharmaceutical products. It offers products for the treatment of ADHD, multiple sclerosis, urticaria, allergic asthma, psoriasis, chronic obstructive pulmonary disorder, migraine, blood diseases, eye disorder, and other diseases. The company is headquartered in Kista, Sweden. | Health Technology |
New Jersey City University Foundation
New Jersey City University Foundation Other Consumer ServicesConsumer Services The New Jersey City University Foundation operates colleges and educational universities. The private company is based in New Jersey. | Consumer Services |
| Deirdres House | |
Mallinckrodt Medical, Inc. (US)
Mallinckrodt Medical, Inc. (US) Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Medical, Inc. is a pharmaceutical company based in St. Louis. The American company manufactures pharmaceutical products. | Health Technology |
